Cargando…
75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study
BACKGROUND: The primary analysis of the STAT study demonstrated the feasibility, efficacy, and safety of using DTG/3TC as a first-line regimen in a test-and-treat setting through 24 weeks, with therapy adjustments for baseline resistance or hepatitis B virus (HBV) co-infection. Here we present secon...
Autores principales: | Rolle, Charlotte-Paige M, Berhe, Mezgebe, Singh, Tulika, Ortiz, Roberto, Wurapa, Anson K, Ramgopal, Moti, Jayaweera, Dushyantha, Leone, Peter, Matthews, Jessica, Cupo, Michael, Underwood, Mark, Angelis, Kostas, Wynne, Brian, Merrill, Deanna, Nguyen, Christopher T, van Wyk, Jean A, Zolopa, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644878/ http://dx.doi.org/10.1093/ofid/ofab466.075 |
Ejemplares similares
-
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023) -
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021) -
1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
por: Pierone, Gerald, et al.
Publicado: (2022) -
Cardiovascular risk factors and Parkinson's disease in 500,000 Chinese adults
por: Kizza, Jennifer, et al.
Publicado: (2019) -
Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load
por: Sterrantino, Gaetana, et al.
Publicado: (2014)